Eplerenone-13C, d3

CAT:
804-HY-B0251S1
Size:
1 Each
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Eplerenone-13C, d3 - image 1

Eplerenone-13C, d3

  • Description:

    Eplerenone-13C, d3 (Epoxymexrenone-13C, d3) is 13C labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB) . Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) [1][2].
  • Product Name Alternative:

    Epoxymexrenone-13C, d3
  • UNSPSC:

    12352211
  • Target:

    Endogenous Metabolite; Isotope-Labeled Compounds; Mineralocorticoid Receptor
  • Related Pathways:

    Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor
  • Applications:

    Cancer-programmed cell death
  • Field of Research:

    Cancer; Cardiovascular Disease
  • Smiles:

    C[C@@]12[C@]34[C@]([C@@H](CC1=CC(CC2)=O)C(O[13C]([2H])([2H])[2H])=O)([H])[C@@]5([H])[C@](C[C@@]3([H])O4)([C@]6(CCC(O6)=O)CC5)C
  • Molecular Formula:

    C23 13CH27D3O6
  • Molecular Weight:

    418.50
  • References & Citations:

    [3]Shlomo Keidar, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003 Jun;41 (6) :955-63. |[4]Dhillon, S., Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. Drugs, 2013. 73 (13) : p. 1451-62.|[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Myron H Weinberger, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002 Aug;15 (8) :709-16.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Isotope-Labeled Compounds
  • Clinical Information:

    No Development Reported